India’s first Covid-19 vaccine, Covaxin, is recently in the clinical trial phase, the government said. Through associations, India has two other candidate vaccines in the country: the AZ/Oxford viral vector vaccine and the Novavax protein subunit vaccine.
Here are the top 10 updates on the status and trials of Covid-19 vaccines:
1) Dr. Vinod K Paul of Niti Aayog, who is the chairman of the Authorized Group 1 Medical Emergency Management Plan, informed the Commission of the COVID vaccine progression procedure in India and around the world.
2) Dr. Paul stated that 29 applicants worldwide, two Indians, are in clinical trials. Of these, six of these vaccines are in Phase 3.
3) In India, The Candidate Vaccine of Bharat Biotech on an inactivated virus purchased through ICMR is in Phase II with ZydusCadila’s candidate in viral DNA.
4) ICMR, which works with the pharmaceutical company to expand the vaccine, has decided on 12 medical institutes in the country where the trial would be conducted.
5) The Oxford Covid-19 vaccine candidate vaccine developed through the Serum Institute of India is already in Phase III testing in Maharashtra and other states. The ICMR had stated in the past that the Oxford “Covidshield” vaccine was in Phase 2 (b) and Phase 3.
6) The Pune-based drug manufacturer has decided at 17 sites in India to conduct the trial. A total of 1,600 applicants will participate in the study, of which at least five volunteers have already been inoculated with the “Covishield” vaccine in the last two days.
7) The Government has also been informed of the National Panel for the Administration of Vaccines against COVID-19. The organization is guilty of facilitating the development of vaccines, adding garage tests and problems, addressing funding, managing threats, establishing potential beneficiaries and their reference order, logistics, scaling, the virtual system, and defining recipient selection principles. and the definition of the clinical basis for vaccine selection. So far, 3 panel meetings have been held.
8) Meanwhile, an approved vaccine is expected to succeed in the Indian market until the first quarter of 2021, Bernstein said in a report.
9) “Knowledge of Phase I/II seems promising in terms of vaccine protection and ability to provoke an immune response,” he said. “We are confident that there will be an approved vaccine on the market until the first quarter of 2021 in India,” the report said.
Meanwhile, the COVID-19 count in India exceeded 34 lakh with a one-day peak of 76472 cases, while the number of recoveries rose to 26.48998, bringing the recovery rate to 76.47% on Saturday, according to Union Health. Ministry. However, the rate of cases in the country was reduced by an extra 1.81%. “India has one of the lowest COVID-19 mortality rates in the world,” EU Health Minister Dr Harsh Vardhan said at the meeting.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.